Ignite Creation Date:
2024-05-06 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 2:50 PM
Study NCT ID:
NCT05699746
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-01-26
First Post:
2023-01-16
Brief Title:
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
A Randomized Controlled Trial of CAPEOX vs Observation in Early-stage Colorectal Cancer Patients With Positive MRD After Curative Surgery
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis and are not recommended to receive adjuvant chemotherapy after radical surgery With the advances in liquid biopsy technology detection of circulating tumor DNA ctDNA can effectively identify early-stage cancer patients with minimal residual disease MRD after surgery According to the growing number of MRD studies in solid tumor colorectal cancer patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse within two years This study aims to assess the efficacy of adjuvant chemotherapy with capecitabine plus oxaliplatin CAPEOX compared with conventional observation in MRD-positive patients with stage I colorectal cancer and clinically low-risk stage II colon cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None